Optimization of Heart Failure Treatment by Heart Rate Reduction.

Cardiovascular comorbidities Chronic heart failure Heart rate Heart rhythm Ivabradine Patient outcomes

Journal

International journal of heart failure
ISSN: 2636-1558
Titre abrégé: Int J Heart Fail
Pays: Korea (South)
ID NLM: 101775659

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 23 10 2019
accepted: 12 11 2019
entrez: 20 10 2022
pubmed: 9 12 2019
medline: 9 12 2019
Statut: epublish

Résumé

Heart failure (HF) treatment should be optimized in addition to guideline-directed and recommended drugs to achieve an appropriate heart rate (i.e. 50-60 bpm) by ivabradine in patients with a heart rate >70 bpm in sinus rhythm and with an ejection fraction ≤35%. Heart rate reduction was to reduce cardiovascular death and HF hospitalization dependent on baseline resting heart rate. In particular in patients at a heart rate >75 bpm, a reduction in cardiovascular death, all-cause death, HF death, HF hospitalization and all-cause hospitalization has been observed. The optimal heart rate achieved appears to be between 50-60 bpm, if well tolerated as in these patients the lowest event rate is observed on treatment. Heart rate reduction is, therefore, a treatable risk factor in chronic HF. Observational studies support the concept that it is a risk indicator in other cardiovascular and non-cardiovascular conditions. Whether heart rate reduction is also modifying risk in other conditions than chronic HF should be explored in prospective clinical trials.

Identifiants

pubmed: 36263079
doi: 10.36628/ijhf.2019.0009
pmc: PMC9536732
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1-11

Informations de copyright

Copyright © 2020. Korean Society of Heart Failure.

Déclaration de conflit d'intérêts

Conflict of Interest: MB received grants and honoraria from Servier and was Executive Boar Member of the SHIFT trial.
The other authors have no financial conflicts of interest.

Références

Am J Cardiol. 2016 Dec 15;118(12):1948-1953
pubmed: 27780557
Int J Cardiol. 2010 Apr 30;140(3):279-86
pubmed: 19095316
Ann Intern Med. 2009 Jun 2;150(11):784-94
pubmed: 19487713
Am J Cardiol. 2008 Mar 15;101(6):865-9
pubmed: 18328855
Clin Pharmacol Ther. 1998 Aug;64(2):192-203
pubmed: 9728900
Drugs. 2004;64(16):1757-65
pubmed: 15301560
Int J Cardiol. 2013 Dec 10;170(2):182-8
pubmed: 24225201
JAMA. 2000 Mar 8;283(10):1295-302
pubmed: 10714728
Am Heart J. 2013 Feb;165(2):216-25
pubmed: 23351825
Am J Cardiol. 2015 Dec 15;116(12):1890-7
pubmed: 26508709
Am J Cardiol. 2014 Feb 1;113(3):497-503
pubmed: 24332674
Eur J Heart Fail. 2017 Oct;19(10):1230-1241
pubmed: 28627045
Am Heart J. 1987 Jun;113(6):1489-94
pubmed: 3591616
Am J Hypertens. 2009 Feb;22(2):151-5
pubmed: 19151693
Circulation. 1992 May;85(5):1743-50
pubmed: 1572031
Eur J Heart Fail. 2004 Aug;6(5):663-8
pubmed: 15302016
Eur J Heart Fail. 2014 Jan;16(1):103-11
pubmed: 24453099
Clin Res Cardiol. 2013 Jan;102(1):11-22
pubmed: 22575988
Circulation. 2001 Mar 13;103(10):1428-33
pubmed: 11245648
Heart Fail Rev. 2013 Mar;18(2):107-22
pubmed: 22581217
Int J Cardiol. 2016 Aug 15;217:7-11
pubmed: 27167103
Circ Heart Fail. 2013 May;6(3):403-10
pubmed: 23599310
Eur Heart J. 2002 Aug;23(16):1301-8
pubmed: 12175667
Eur J Heart Fail. 2008 Jun;10(6):550-5
pubmed: 18486549
Diabetes Care. 2008 Feb;31(2):335-9
pubmed: 17959868
Hypertension. 2010 Feb;55(2):567-74
pubmed: 20038750
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
Lancet. 2010 Sep 11;376(9744):886-94
pubmed: 20801495
J Am Coll Cardiol. 2012 May 29;59(22):1938-45
pubmed: 22617188
Eur J Heart Fail. 2014 Apr;16(4):426-34
pubmed: 24504937
Eur J Heart Fail. 2016 Sep;18(9):1182-9
pubmed: 27210035
Eur J Heart Fail. 2015 May;17(5):518-26
pubmed: 25801408
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Intern Med. 2015 Jul;278(1):38-49
pubmed: 25431275
Eur Respir J. 2013 Aug;42(2):341-9
pubmed: 23143550
Circulation. 2002 Oct 22;106(17):2194-9
pubmed: 12390947
Eur J Heart Fail. 2013 Aug;15(8):885-91
pubmed: 23460732
Eur J Heart Fail. 2013 Sep;15(9):1044-52
pubmed: 23696612
Eur J Heart Fail. 2015 Dec;17(12):1294-301
pubmed: 26377342
N Engl J Med. 2014 Sep 18;371(12):1091-9
pubmed: 25176136
Eur J Heart Fail. 2013 Nov;15(11):1296-303
pubmed: 23803951
Eur J Heart Fail. 2014 Jul;16(7):810-6
pubmed: 24961493
JACC Heart Fail. 2013 Dec;1(6):488-96
pubmed: 24622000
Adv Ther. 2015 Feb;32(2):108-19
pubmed: 25700807
Am Heart J. 1991 Jan;121(1 Pt 1):172-7
pubmed: 1985358
Eur J Heart Fail. 2017 Feb;19(2):250-252
pubmed: 27917598
Eur J Clin Pharmacol. 2005 Jul;61(5-6):445-51
pubmed: 15940531
Lancet. 2008 Sep 6;372(9641):807-16
pubmed: 18757088
Eur J Heart Fail. 2014 Jan;16(1):76-85
pubmed: 23928650
Lancet. 2008 Sep 6;372(9641):817-21
pubmed: 18757091
Clin Investig. 1992 May;70(5):421-5
pubmed: 1600353

Auteurs

Michael Böhm (M)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Yvonne Bewarder (Y)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Ingrid Kindermann (I)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Jonathan Slawik (J)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Jan Wintrich (J)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Christian Werner (C)

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

Classifications MeSH